Become a fan of Slashdot on Facebook


Forgot your password?
Medicine Science

FDA Approves First Drug Aimed at Women With Inherited Breast Cancer ( 33

U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene. From a report: The Food and Drug Administration on Friday approved AstraZeneca PLC's Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy. The drug has been on the market since 2014 for ovarian cancer, and is the first in a new class of medicines called PARP inhibitors to be approved for breast cancer. PARP inhibitors prevent cancer cells from fixing problems in their DNA. Lynparza will cost $13,886 per month without insurance, according to AstraZeneca. The company is offering patients financial assistance.
This discussion has been archived. No new comments can be posted.

FDA Approves First Drug Aimed at Women With Inherited Breast Cancer

Comments Filter:
  • by moehoward ( 668736 ) on Monday January 15, 2018 @06:26PM (#55934479)

    I'm male, but have this genetic condition. I do have female family members who have suffered greatly. Many in my close and extended family have died because of this defect. Men are affected as well, but not as badly as women. I'm at much higher risk for prostate, colon, and pancreatic cancers.

    I have known about my situation for about 20 years. I have even donated to UPenn's cancer center (where this drug was developed) in the past many years. It is inspiring to see real progress and real medicine happening.

    I'm not outraged at the price at all. I've visited the labs and researchers who do this work. It is so freaking complicated, messy, and heartbreaking. PARP inhibitors have been our real hope for the women in the family. One family member who died a couple of years ago was part of a trial for this class of medication.

    The road to curing these diseases is very long, and this is a great step in the right direction. I'm glad to see such an uplifting story on Slashdot (for me personally).

  • "The median progression-free survival for patients taking Lynparza was 7 months compared to 4.2 months for patients taking chemotherapy only.

    OK, so we're looking at $40k for an extra 3 months of life? I'm not sure what to think. But it does point out the importance of discussing end-of-life decisions. Remember when Republicans were screaming about their made-up "death panels"? There weren't any death panels, of course, but there was language suggesting doctors should talk to their patients about discus

    • by Miser ( 36591 )

      I am inclined to agree with you.

      Reminds me of that advertisement for the drug Optivo. "A chance to live longer". Then you read the fine print. 2-3 months longer. Let's say 6 months to be generous. Sorry, but to me that's not worth it. I want a cure/remission. Why all the research to postpone the inevitable?

      That's also why I believe advanced directives should include a clause that if there is a clear, terminal illness at play (no cure, no hope of cure, x months to live) give me that morphine IV, le

I go on working for the same reason a hen goes on laying eggs. -- H.L. Mencken